scispace - formally typeset
S

Silvano Sozzani

Researcher at Sapienza University of Rome

Publications -  352
Citations -  47443

Silvano Sozzani is an academic researcher from Sapienza University of Rome. The author has contributed to research in topics: Chemokine & Chemokine receptor. The author has an hindex of 98, co-authored 335 publications receiving 43598 citations. Previous affiliations of Silvano Sozzani include University of Turin & Brescia University.

Papers
More filters
Journal ArticleDOI

Dendritic cell recruitment and activation in autoimmunity.

TL;DR: This review aims at critically summarizing the current literature concerning selected aspects of DC biology that, when altered, facilitate autoimmunity, including mechanisms of tissue entry and accumulation, mechanisms of activation and orchestration of the immune balance by cytokine production.
Journal ArticleDOI

Type I interferons in systemic autoimmunity

TL;DR: Recent acquisitions about IFN-I biology are underline, with a focus on the relevance of the induction of some autoimmune diseases, such as systemic lupus erythematosus, systemic sclerosis, rheumatoid arthritis, dermato/polymiositis, and Sjogren's syndrome.
Journal ArticleDOI

Rapid induction of arachidonic acid release by monocyte chemotactic protein-1 and related chemokines. Role of Ca2+ influx, synergism with platelet-activating factor and significance for chemotaxis.

TL;DR: The results presented here show that the Cys-Cys chemokines MCP-1, LD78/MIP1 alpha, and RANTES cause rapid release of arachidonic acid in monocytes and that this may be important in inducing monocyte chemotaxis.
Journal ArticleDOI

Suppression of metastatic hemangiosarcoma by a parvovirus MVMp vector transducing the IP-10 chemokine into immunocompetent mice.

TL;DR: A new recombinant vector, MVMp/IP-10 is created, transducing the immunoactive, antiangiogenic chemokine IP-10, and used to treat syngeneic tumors grown in immunocompetent mice, demonstrating that MVMs can aid the treatment of vascular tumors and that autonomous parvovirus-based vectors can be considered potent tools for cancer gene therapy purposes.